258 related articles for article (PubMed ID: 17407626)
1. Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study.
Stein DJ; Andersen EW; Tonnoir B; Fineberg N
Curr Med Res Opin; 2007 Apr; 23(4):701-11. PubMed ID: 17407626
[TBL] [Abstract][Full Text] [Related]
2. Escitalopram in obsessive-compulsive disorder: response of symptom dimensions to pharmacotherapy.
Stein DJ; Carey PD; Lochner C; Seedat S; Fineberg N; Andersen EW
CNS Spectr; 2008 Jun; 13(6):492-8. PubMed ID: 18567973
[TBL] [Abstract][Full Text] [Related]
3. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder.
Baldwin DS; Cooper JA; Huusom AK; Hindmarch I
Int Clin Psychopharmacol; 2006 May; 21(3):159-69. PubMed ID: 16528138
[TBL] [Abstract][Full Text] [Related]
4. High-dose escitalopram for the treatment of obsessive-compulsive disorder.
Rabinowitz I; Baruch Y; Barak Y
Int Clin Psychopharmacol; 2008 Jan; 23(1):49-53. PubMed ID: 18090508
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
Pelissolo A
Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243
[TBL] [Abstract][Full Text] [Related]
6. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
[TBL] [Abstract][Full Text] [Related]
7. Quality of life outcomes in patients with obsessive-compulsive disorder: relationship to treatment response and symptom relapse.
Hollander E; Stein DJ; Fineberg NA; Marteau F; Legault M
J Clin Psychiatry; 2010 Jun; 71(6):784-92. PubMed ID: 20492845
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
9. A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder.
Denys D; van Megen HJ; van der Wee N; Westenberg HG
J Clin Psychiatry; 2004 Jan; 65(1):37-43. PubMed ID: 14744166
[TBL] [Abstract][Full Text] [Related]
10. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder.
Denys D; van der Wee N; van Megen HJ; Westenberg HG
J Clin Psychopharmacol; 2003 Dec; 23(6):568-75. PubMed ID: 14624187
[TBL] [Abstract][Full Text] [Related]
11. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.
Boulenger JP; Huusom AK; Florea I; Baekdal T; Sarchiapone M
Curr Med Res Opin; 2006 Jul; 22(7):1331-41. PubMed ID: 16834832
[TBL] [Abstract][Full Text] [Related]
13. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder.
Bielski RJ; Bose A; Chang CC
Ann Clin Psychiatry; 2005; 17(2):65-9. PubMed ID: 16075658
[TBL] [Abstract][Full Text] [Related]
14. Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial.
Geller DA; Wagner KD; Emslie G; Murphy T; Carpenter DJ; Wetherhold E; Perera P; Machin A; Gardiner C
J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1387-96. PubMed ID: 15502598
[TBL] [Abstract][Full Text] [Related]
15. Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: escitalopram vs paroxetine.
Boulenger JP; Hermes A; Huusom AK; Weiller E
Curr Med Res Opin; 2010 Mar; 26(3):605-14. PubMed ID: 20067433
[TBL] [Abstract][Full Text] [Related]
16. Paroxetine in the treatment of obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study in Japanese patients.
Kamijima K; Murasaki M; Asai M; Higuchi T; Nakajima T; Taga C; Matsunaga H
Psychiatry Clin Neurosci; 2004 Aug; 58(4):427-33. PubMed ID: 15298657
[TBL] [Abstract][Full Text] [Related]
17. New treatment options for OCD.
Fineberg NA
Int J Psychiatry Clin Pract; 2007; 11 Suppl 2():24-30. PubMed ID: 24926869
[TBL] [Abstract][Full Text] [Related]
18. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder.
Lepola U; Wade A; Andersen HF
Int Clin Psychopharmacol; 2004 May; 19(3):149-55. PubMed ID: 15107657
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: data from the "Boulenger" study].
Chauvet-Gélinier JC
Encephale; 2010 Oct; 36(5):425-32. PubMed ID: 21035633
[TBL] [Abstract][Full Text] [Related]
20. Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study.
Baldwin DS; Huusom AK; Maehlum E
Br J Psychiatry; 2006 Sep; 189():264-72. PubMed ID: 16946363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
